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ABSTRACT
Objective: To explore the experiences of adolescents
with type 1 diabetes mellitus (T1DM) and their parents
taking part in an overnight closed loop study at home,
using qualitative and quantitative research methods.
Research design and methods: Adolescents aged
12–18 years on insulin pump therapy were recruited to
a pilot closed loop study in the home setting.
Following training on the use of a study insulin pump
and continuous glucose monitoring (CGM),
participants were randomized to receive either real-time
CGM combined with overnight closed loop or real-time
CGM alone followed by the alternative treatment for an
additional 21 days with a 2–3-week washout period in
between study arms. Semistructured interviews were
performed to explore participants’ perceptions of the
impact of the closed loop technology. At study entry
and again at the end of each 21-day crossover arm of
the trial, participants completed the Diabetes
Technology Questionnaire (DTQ) and Hypoglycemia
Fear Survey (HFS; also completed by parents).
Results: 15 adolescents and 13 parents were
interviewed. Key positive themes included reassurance/
peace of mind, confidence, ‘time off’ from diabetes
demands, safety, and improved diabetes control. Key
negative themes included difficulties with calibration,
alarms, and size of the devices. DTQ results reflected
these findings. HFS scores were mixed.
Conclusions: Closed loop insulin delivery represents
cutting-edge technology in the treatment of T1DM.
Results indicate that the psychological and physical
benefits of the closed loop system outweighed the
practical challenges reported. Further research from
longitudinal studies is required to determine the long-
term psychosocial benefit of the closed loop technology.
Fear of hypoglycemia, particularly nocturnal,
is common1 2 and a serious complication of
insulin treatment in people with type 1 dia-
betes mellitus (T1DM). It represents a crit-
ical problem in the management of the
disease and causes psychological distress for
many parents of children with T1DM.3
Severe hypoglycemia can potentially lead to
seizures and coma and may play a role as a
precipitating factor in cardiac arrhythmias
resulting in the ‘dead in bed’ syndrome.4
Nocturnal hypoglycemia is a special
concern in the pediatric population, where a
high incidence has been reported.5 6
Intensiﬁcation of insulin treatment and strict
glycemic control have been shown to cause
further increases in rates of hypoglycemia in
this population.7 8 Risk of hypoglycemia
represents a major obstacle to the achieve-
ment of optimal blood glucose levels.9
The development of the artiﬁcial pancreas
(AP), a system that combines glucose moni-
toring with computer-based algorithm dic-
tated insulin delivery, may provide a solution
and represent an additional realistic treat-
ment option for people with T1DM. The
vital component of a closed loop system is a
computer-based algorithm. Other compo-
nents include a real-time continuous glucose
monitor and an infusion pump to titrate and
deliver insulin.10 The role of the control
algorithm is to translate, in real time, the
information it receives from the glucose
monitor and to compute the amount of
insulin to be delivered by the pump.
Key messages
▪ Closed loop insulin delivery represents
cutting-edge technology in the treatment of type
1 diabetes.
▪ The psychosocial aspects of a closed loop
require investigation to ensure minimal burden
on participants and support with managing
expectations.
▪ The psychological benefits of closed loop tech-
nology show promising benefits in terms of
important patient-centered and family-centered
outcomes.
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There has been no previous prolonged evaluation of a
closed loop under free-living conditions. The purpose of
this study, alongside the assessment of the safety and efﬁ-
cacy of an overnight closed loop at home setting, was to
explore the experiences of adolescents and their parents
taking part in the study, using qualitative and quantita-
tive research methods.
PARTICIPANTS AND METHODS
Sixteen adolescents with T1DM aged 12–18 years were
recruited to an open-label, single-center, randomized
two-period crossover study.11 This assessed the efﬁcacy,
safety, and utility of real-time continuous subcutaneous
glucose monitoring (FreeStyle Navigator, Abbott
Diabetes Care, Alameda, California, USA) combined
with an overnight closed loop glucose control in the
home setting in comparison with real-time continuous
subcutaneous glucose monitoring alone in adolescents
with T1DM on subcutaneous insulin infusion pump
therapy (Dana R Diabecare, Sooil, Seoul, South Korea).
Participants connected to the system in the evening and
disconnected on waking in the morning. Closed loop
technology was not used during the day or for meals.
Every 12 min, the treat-to-target algorithm calculated a
new insulin infusion rate, which was automatically set on
the study pump.11
A mixed methods psychosocial evaluation was con-
ducted to determine the utility of the device in terms of
participants’ perceptions of lifestyle change, diabetes
management, and fear of hypoglycemia. Participants
aged 16 years and older and parents or guardians of par-
ticipants aged younger than 16 years signed informed
consent; assent was received from minors.
As part of the study, participants received prestudy
training on the use of a study insulin pump and study
real-time continuous glucose monitoring (CGM), and
then a minimum of 7 days of masked CGM data was
recorded over a training period and used to optimize
insulin therapy. Participants underwent two interven-
tions: overnight closed loop combined with real-time
CGM for 21 nights and the real-time CGM alone for
21 days with a 2–3 week washout period. The order of
the two interventions was random.
Qualitative methods
Semistructured interviews to explore participants’ per-
ceptions of the impact of the closed loop technology on
their lived experience were designed in collaboration
with the clinical research team. The interview schedule
was then piloted on four potential participants for
usability, relevance, and acceptability. These participants
were not included in the study. The feedback was posi-
tive with minor revisions suggested, and the interview
schedule was revised in line with this. All adolescents
taking part in the closed loop study were invited to par-
ticipate in the qualitative interview study as well as one/
both of their parents, and 15 of the 16 participants
elected to do so.
On completion of the study, participants/parents were
invited to partake in an audio-recorded telephone inter-
view conducted by KDB. All interviews were conducted
within 2 weeks of the end of the trial. Audiotapes were
transcribed with all identifying details removed.
A thematic approach was used to analyze the data,
informed by the method of constant comparison, and
involved concurrent data collection and analysis.12
Following transcription, KDB and TT performed inde-
pendent analyses, reading each participant’s interview in
full before performing cross-comparisons to identify
continuities and differences between accounts. A joint
thematic analysis was used to compare interpretations
and resolve any differences in interpretation to reach
agreement on recurrent themes and ﬁndings.12 This
analysis was used to develop a coding framework which
captured original research questions and emerging
ﬁndings.
Content analysis focused on the number/frequency of
‘instances’, their context, meaning, and whether they
were common across participants. Thematic analysis con-
centrated on identifying key themes arising with a view
to understanding the experiences of adolescents and
their parents, exploring connections between themes,
and identifying how closed loop technology affects every-
day living and factors important to quality of life in ways
that are important to adolescents and their parents.
Quantitative methods
At study entry and again at the end of two interventions,
each adolescent completed the Diabetes Technology
Questionnaire (DTQ). This is a 30-item measure of the
impact of, and satisfaction with, technological tools that
may be used in the management of T1DM.13
Participants were asked to rate their agreement or dis-
agreement with statements regarding the speciﬁc com-
plement of diabetes technologies (ie, meter, pump,
continuous glucose monitor, closed loop AP). Items
related to ‘current’ satisfaction and impact as well as
‘change’ in satisfaction and impact since the new tech-
nology was added to the participant’s regimen and admi-
nistered at the end of the two 21-day crossover periods.
The DTQ yields separate scores for ‘current’ (How
much is this a problem now?) and ‘change’ (How has it
changed compared to before the study?) subscales. After
reverse scoring of some items, higher scores are indica-
tive of more favorable satisfaction and impact ratings of
the technology. Unpublished psychometric data based
on a sample of 115 youths enrolled in a CGM trial indi-
cate that the internal consistency (Cronbach’s α) was
0.96 for parents and 0.94 for adolescents, split half reli-
ability was 0.87 for parents and adolescents, 3-month
test–retest reliability was 0.68 for parents and 0.59 for
adolescents, and parent–adolescent agreement was 0.61.
Parents and adolescents also completed the
Hypoglycemia Fear Survey (HFS),14 a 23-item measure
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that assesses the frequencies of certain behaviors that
are designed to avoid hypoglycemia (10 items) and of
sources of worry or anxiety about hypoglycemia (13
items). Numerous studies have supported the instru-
ment’s psychometric properties.15 16
RESULTS
Qualitative interviews
Fifteen adolescent participants agreed to be interviewed
along with 13 parents (12 mothers; 1 father). The two
eldest participants did not wish for their parent to be
interviewed. Interview duration ranged from 14 to
28 min for adolescents (mean 22 min) and from 25 to
65 min for parents (mean 36 min). Parent interviews
always lasted longer than those of their child; boys’ inter-
views were shorter than girls’ interviews. Only one
parent from each family chose to be interviewed.
Participants included nine males and six females, age
15.6 (2.1) years; diabetes duration 7.2 (4.3) years; gly-
cated hemoglobin 8.0 (0.9) % (63.9 (9.3) mmol/mol);
body mass index (BMI) 22.4 (3.7) kg/m2; BMI z-score
0.8 (0.8); insulin pump therapy duration of 3.0
(2.3) years.
Twelve adolescents directly commented on having per-
ceived improved blood glucose levels as a result of using
the closed loop system, which was mirrored by seven of
the parents. Twelve parents and adolescents reported
feeling safe using the closed loop system; a negative inci-
dence for one parent–adolescent pair resulted in a loss
of this conﬁdence in the system. On one occasion, the
closed loop was connected when the participant had a
very high blood glucose level. The participant assumed
that it would regulate to within the target; however, it
did not do so and no alarm sounded, so no manual cor-
rection insulin dose was given, resulting in high blood
glucose until the next morning (the high overnight
glucose was retrospectively explained by the missed
evening meal bolus and possibly incorrect pump
priming). This did not deter the family from continuing
participation in the trial.
Six adolescents spoke directly about their improved
sleep and how it led to ‘waking up normal’ and
facilitated improved diabetes control during the day. Six
parents also commented on sleep, but focused on
reduced anxiety and increased conﬁdence that their
child would wake up with ‘normal’ blood glucose levels.
Seven parents commented that the closed loop system
enabled them to feel less anxious about their child’s
diabetes.
Difﬁculties with calibration, alarms, and size of the
device were key concerns. Key aspects of closed loop
technology are included in table 1.
There was 100% agreement between parents and ado-
lescents on the key beneﬁts of the closed loop system.
Agreement focused on safety, improved blood glucose
control, trust in the device, and reassurance without
having to get up in the night to do a blood test. Tables 2
and 3 present the details of key positive and negative
themes.
Deeper exploration showed additional beneﬁts and
downsides; for example, one parent reported on the
alarms being a downside (004). Additional downsides
were reported by participant 004 who explained that “it
[the CGM transmitter] was uncomfortable to lie on…, it
was inconvenient to plug in…” and that when the device
went off [alarm] he believed his dad felt powerless “as
he had to leave it up to the system.” Participant 002 and
their parent commented on the ‘constant blood sugar
level’ and ‘numbers were perfect’ and the parent of par-
ticipant 002 added that they ‘didn’t want to give it back
and would deﬁnitely keep it’.
The concept of feeling ‘normal’ as opposed to ‘dia-
betic’ was raised by two adolescent participants, perhaps
reﬂecting the stigma associated with diabetes and the
challenges of living with it.1 No parent commented on
this. Hope for the future was expressed by several partici-
pants, for example, ‘I liked the idea of how good it
could be’ (003) as well as satisfaction that they were
taking part in an important clinical research trial that
would ultimately beneﬁt other people with diabetes.
Ten parents and 15 adolescents would recommend
the closed loop technology. There was agreement
between the 10 parent–adolescent pairs in their
recommendation.
Diabetes Technology Questionnaire
The DTQ measure completed by adolescents covers
similar content as the qualitative interviews, albeit with a
forced choice questionnaire format. Results for the
‘current’ subscale showed that, at baseline, 21% of
answers indicated either ‘very much’ or ‘some’ in
response to the question “Is this a problem now?” com-
pared with 14.7% following the closed loop treatment.
Corresponding proportions of answers indicative of ‘Not
much at all’ were 57.7% and 59.1%, respectively. Results
for the ‘change’ subscale indicated that 8.7% of
responses were indicative of ‘Worse or Much Worse’ fol-
lowing the closed loop treatment with 20.5% responses
for ‘Better or Much Better’. The small number of
Table 1 Key aspects of a closed loop
Issue
Positive Negative
Parent Adolescent Parent Adolescent
Improved sleep 7 9
Reduced anxiety 9 −
Stable blood
glucose levels
9 15
Felt safe 14 15
Alarms/beeping 3 6
Uncomfortable − 3
Too big 4 6
Calibration issues 5 4
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participants precluded inferential statistical analyses of
these results.
As an alternative method of exploring the DTQ results
in greater detail, table 4 summarizes the ﬁve DTQ
‘change’ subscale items that reﬂected the most improve-
ment and the ﬁve items reﬂecting the most worsening
relative to the participants’ circumstances prior to the
study. As table 4 shows, the top four items reﬂecting
improvement clustered around reduced anxiety related
to hyperglycemia and hypoglycemia (both with 66.7% of
responses of ‘Much Better’ or a ‘Little Better’) and
around effort to prevent these glycemic excursions
(60% and 53.3%, respectively). The remaining item
reﬂecting the patient-reported beneﬁt of the closed
loop system concerned ensuring that the right insulin
dose is given when meals are skipped or delayed (40%
positive responses). No other DTQ item received more
than 33.3% of responses in these positive categories
and, for 12 of the 30 items, fewer than 10% of respon-
dents indicated that their closed loop experience had
been ‘Much Better’ or ‘A Little Better’ when compared
with their prestudy experiences on those same
dimensions.
Conversely, table 4 also shows that a sizable minority of
participants reported worsened outcomes relative to
their past experience regarding certain aspects of the
closed loop experience. The items that were most likely
to engender responses of ‘Much Worse’ or ‘A Little
Worse’ were concerned with carrying and using several
devices (40%), trouble sleeping (33.3%), perhaps
Table 3 Key negative themes
Theme and participant examples ID
Calibration difficulties/frustration when equipment ‘fails’
“Sometimes it would stop working for a few
minutes…every 5th day”
(013)
“It would sometimes turn off during the night, it
sometimes wouldn’t connect which took quite a
long time to sort out…once or twice a week”
(013)
“The battery life…It wasn’t very good” (007)
“Do it [calibrate] where you won’t be seen or it
won’t be about midnight when you have to
calibrate”
(007)
Size and alarms
“Just having this little brick on my arm really…Just
the size of it”
(002)
“Probably the alarm because they were just really
loud”
(010)
“It was quite big and I’d quite like to have a
slightly littler one”
(012)
“Once we had a problem with the pump, it was
alarming all the time”
(005a)
Accuracy/trust
“Maybe it won’t recognise that I have taken quite
a lot of insulin before and it would give me more
insulin and then I’ll end up having a crashing
hypo”
(008)
“It wasn’t the most reliable system…Your bloods
weren’t always what they said it was”
(001)
“It was a bit hit and miss…you couldn’t rely on it
completely”
(003)
“I didn’t really trust it because I think for a whole
day I was using it, it didn’t give any insulin”
(006)
Discomfort/painful
“I wasn’t allowed to roll on my side or lie on my
front because…the thing in my tummy was like,
kept beeping and it set off alarms and stuff”
(006)
“The implants for the pump, they were annoying…
the needle was sore”
(008)
“There was one time when I did actually rip the
sensor out of my arm after a rowing session, I
was just like ‘oh…I just can’t’…”
(008)
Table 2 Key positive themes
Theme and participant examples ID
Reassurance/peace of mind
“The reassurance really…It was perfect because
whatever happened it seemed to take control of it”
(009a)
“Knowing that I was going to wake up on a good
number”
(004)
“My parents didn’t have to worry so much about
what was happening”
(002)
“I felt I could completely trust it at night and I felt
completely relaxed about it being there”
(004a)
Confidence and ‘time off’ from diabetes demands
“I could rely on it and know that I would be alright
in the morning”
(006)
“That you could just hook it up and it does it all for
you”
(011)
“If you always wake up on a good number then it
kind of sets you up for the rest of the day”
(004)
Safety
“Knowing that they’re going to be OK in the
night…that’s a safety thing”
(004a)
“At night I didn’t have to worry about being
diabetic, I just thought, leave it”
(006)
“It was good really because it was like having
someone taking care of you”
(010)
“It always seemed to work and once I’d had it a
couple of nights I knew it worked and it was good”
(012)
Improved diabetes control
“The perfect sugar control overnight…” (015)
“My improved HbA1c was probably best for me…” (001)
“It really did keep my blood sugar within a very
tight range all through the night …”
(008)
“…cos I was lower I could do more, I could
concentrate better…”
(013)
Being able to get a good night’s sleep
“For the first time in 10 years I didn’t have to do a
blood test at 11 o’clock at night”
(013a)
“Not having the worry…not having to drag
yourself out of bed testing at 2 or 3 o’clock in the
morning…It was reliable”
(002a)
“I had better sleep, you don’t worry about what
you have to do”
(001)
“Every night we could sleep” (005a)
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associated with the alarms; however, in the interviews,
many participants and parents reported better sleep,
reacting to alarms (33.3%), pain or discomfort (21.4%),
and feeling that devices run one’s life (20%). Negative
outcomes of closed loop use were reported somewhat
less often by participants than were the beneﬁts, and all
had to do with various forms of intrusion into daily life.
Hypoglycemia Fear Survey
Mean±SD HFS total scores obtained from adolescents
declined very slightly from the baseline level of 60.1±1.2
to 58.0±0.9 after the closed loop phase and 54.8±1.1
after the open loop phase. For parents, mean HFS total
scores increased from 65.7±1.4 at baseline to 68.2±1.5
after the closed loop phase and 70.4±1.6 after the open
loop phase. Time spent in hypoglycemia below 70 mg/
dL was low in both periods. The number of nights when
the glucose was below 63 mg/dL for at least 20 min was
lower during closed loop (10% vs 17% nights; p=0.01).
DISCUSSION AND CONCLUSIONS
Closed loop technology represents cutting-edge techno-
logical research in the treatment of T1DM. Restricted to
hospital-based trials until recently, technological
advancements have facilitated a progression to home-
based trials, where it is possible to determine, alongside
clinical and cost-effectiveness, the impact on everyday
living and experiences of participants in terms of
impact, trust, and safety.
Participation in the study was reported as a positive
experience for all participants, with several expressing
hope for the future of diabetes management associated
with the closed loop technology. A key beneﬁt reported
in the interviews by many participants was the positive
impact on their sleep, which somewhat contradicts the
questionnaire responses. This may reﬂect the reduced
anxiety at the same time as sometimes being disturbed
in the night by the alarms of the technology.
Furthermore, the disparity may reﬂect the forced choice
on the questionnaire compared with the reﬂective
nature of the interviews.
Parental fear of hypoglycemia is common, with noctur-
nal hypoglycemia being a particular problem. Many
parents wake up in the night to check their child’s
blood glucose level, with a subsequent impact on sleep
patterns. This affects anxiety levels and daily function-
ing.2 The visual afﬁrmation of stable blood glucose
levels throughout the night was reassuring for partici-
pants. Many commented that waking up on a ‘good
number’ set them up for the rest of the day and the
improved glucose control lasted well into the next
morning, thus aiding concentration and enhancing well-
being at school. Poorer educational attainment for chil-
dren with diabetes is reported and poor sleep may be a
contributing factor to this.
The downsides reported by families were practical dif-
ﬁculties with calibrating the device, insulin infusion set
canula insertions, and inconvenience of the size of the
device. These issues are not related to the closed loop
system but to sensor augmented insulin pump therapy
per se. This perhaps reﬂects the technological world
that we live in and general lack of mechanical sympathy
but, more interestingly, it reﬂects the underlying belief
by all participants that the algorithm would work and
that they had faith in it to do so. One participant and
their family found participation challenging and frigh-
tening at times; however, they were still pleased that they
had taken part.
It is noteworthy that so many adolescent participants
commented on the improved blood glucose control as a
key beneﬁt of the closed loop technology and the poten-
tially reduced risk of long-term complications. A
common misconception suggests that social life is priori-
tized over diabetes at this age; however, the results of
this study do not support this. It may be a consequence
Table 4 Diabetes Technology Questionnaire (DTQ), the five DTQ items on which the largest percentage of closed loop
participants responded ‘Much Better’ or ‘A Little Better’ compared to their experiences prior to the study and the five DTQ
items on which the largest percentages of closed loop participants who responded ‘Much Worse’ or ‘A Little Worse’
Percentage of responding
‘Much Better’ or ‘A Little Better’
Worry or fear about high blood sugar 66.7
Worry or fear about low blood sugar during sleep 66.7
Effort to keep high blood sugar from happening 60.0
Effort to keep low blood sugar from happening 53.3
Getting the right amount of insulin when meals are skipped
or delayed
40.0
Percentage of responding ‘Much Worse’ or ‘A Little
Worse’
Coping with carrying and using several devices 40.0
Trouble sleeping well 33.3
Reacting to all of the alarms from diabetes devices 33.3
Pain or discomfort from insulin injections or pump sets 21.4
Feeling that diabetes devices run my life 20.0
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of greater focus on diabetes management when partici-
pating in a clinical trial; however, the spontaneity with
which adolescents talked about diabetes control and
concern for future complications suggests otherwise and
may in fact reﬂect challenges with communication in
clinic outpatient settings rather than a lack of interest in
diabetes self-management.
A key success of the closed loop system until now is
that it has enabled parents to feel less anxious and more
in control of their child’s diabetes. This reﬂects the
underlying, widely reported generalized increased
anxiety associated with living with diabetes and the spe-
ciﬁc impact on the parents’ own health and quality of
life status.2 The closed loop system provided reassurance,
and for some parents, it was the ﬁrst time they felt conﬁ-
dent that their child would sleep safely throughout the
night since their diagnosis with T1DM, often many years
earlier.
Although the DTQ covers content similar to that dis-
cussed in the qualitative interviews, the differential
effects obtained following open loop versus closed loop
treatment were somewhat less striking than might have
been anticipated given the qualitative ﬁndings. However,
the overall pattern of DTQ ‘change’ subscale scores
shown in table 4 suggests similar ﬁndings regarding the
aspects of closed loop use that were perceived by partici-
pants as beneﬁcial (anxiety about glycemic ﬂuctuations
and the effort required to prevent them) and as intru-
sive (burden of using several devices, sleep disturbance,
excessive alarms, pain or discomfort, and feeling that
the devices control one’s life). The DTQ results there-
fore provide a quantitative complement to the ﬁndings
obtained during the qualitative interviews.
Similar to other pediatric studies using the HFS,
parents reported greater fear of hypoglycemia than did
adolescents at each measurement point.14 The HFS
results also afﬁrmed some ﬁndings of the qualitative ana-
lyses that were performed, showing that adolescents
reported modest decreases in total scores for fear of
hypoglycemia. However, in contrast to the qualitative
results, compared with their baseline HFS scores, parents
reported a slight increase in HFS scores after the closed
loop phase and a marked increase in HFS scores after the
open loop phase. Perhaps formative experience with
CGM and recognition that glycemic ﬂuctuations are
more common and more labile among adolescents than
they had expected caused some parents to experience
heightened anxiety about the threat of hypoglycemia.
The strengths of the current research are that it
explores participants’ subjective experiences of taking
part in the trial and the impact of overnight closed loop
technology on their everyday lives. Furthermore, it pro-
vided an opportunity for parents to explore their fears
and hopes regarding their child’s T1DM, its impact, and
the potential of the closed loop technology. The limita-
tions of the study included the small number of partici-
pants and the telephone, rather than face-to-face,
methodology for interviews. It was considered to be less
intrusive for families and facilitated separate and private
interviews for adolescents and parents. Similarly, the
sample was based on the availability of participants from
the clinical trial, and so it is not possible to know
whether saturation of views was reached.
The qualitative and quantitative methods converged in
supporting the observation that closed loop treatment
carries with it promising beneﬁts in terms of important
patient-centered and family-centered outcomes, but that
integration of closed loop use in daily life will require
advances that reduce the intrusiveness of this technology.
In conclusion, closed loop insulin delivery represents
cutting-edge technology in the treatment of T1DM.
Results indicate that the psychological and physical ben-
eﬁts of the closed loop system outweighed the practical
challenges reported. These qualitative results were
largely conﬁrmed using a quantitative measure, the
DTQ. Further research from longitudinal studies is
required to determine the long-term beneﬁt of the
closed loop technology.
Acknowledgements The authors are grateful to the study volunteers for their
participation. Professor Peter Hindmarsh (University College London) helped
in identifying potential recruits. John Lum ( Jaeb Center) and Jasdip Mangat
(Cambridge University Hospitals NHS Foundation Trust) supported the
development and validation of the closed loop system. Josephine Hayes
(Institute of Metabolic Science, University of Cambridge) provided
administrative support.
Contributors KDB wrote the first draft of the manuscript. TW reviewed and
edited the manuscript and contributed to the results and discussion. AG
provided data management support. All authors researched the data and
reviewed and edited the manuscript. KDB is the guarantor.
Funding Supported by the Juvenile Diabetes Research Foundation
(#22-2006-1113, #22-2007-1801, #22-2009-801, #22-2009-802), Diabetes
UK (BDA07/0003549), National Institute of Diabetes and Digestive and Kidney
Diseases (1R01DK085621), and the National Institute for Health Research
Cambridge Biomedical Research Centre. Abbott Diabetes Care supplied
continuous glucose delivery devices and sensors and modified devices to
facilitate real-time connectivity.
Competing interests RH reports having received speaker honoraria from
Minimed Medtronic, Lifescan, Eli Lilly, BBraun, and Novo Nordisk; serving on
the advisory panel for Animas, Minimed Medtronic, and Eli Lilly; receiving
license fees from BBraun and Beckton Dickinson; and having served as a
consultant to Beckton Dickinson, BBraun, Sanofi, and Profil. RH and DBD
report patent applications.
Ethics approval The study was approved by the local research ethics
committee and Cambridge National Research Ethics Service (NRES).
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement No additional data are available.
Open Access This is an Open Access article distributed in accordance with
the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license,
which permits others to distribute, remix, adapt, build upon this work non-
commercially, and license their derivative works on different terms, provided
the original work is properly cited and the use is non-commercial. See: http://
creativecommons.org/licenses/by-nc/3.0/
REFERENCES
1. Barnard KD, Lloyd CE, eds. Practical psychology and diabetes care.
London: Springer, 2012.
2. Amin R, Ross K, Acerini CL, et al. Hypoglycemia prevalence in
prepubertal children with type 1 diabetes on standard insulin
6 BMJ Open Diabetes Research and Care 2014;2:000025. doi:10.1136/bmjdrc-2014-000025
Clinical care/education/nutrition/psychosocial research
regimen: use of continuous glucose monitoring system. Diabetes
Care 2003;26:662–7.
3. Barnard KD, Royle P, Thomas S, et al. Systematic literature review
into parental fear of acute hypoglycaemia. BMC Paediatr
2010;10:50.
4. Secrest AM, Becker DJ, Kelsey SF, et al. Characterizing sudden
death and dead-in-bed syndrome in type 1 diabetes: analysis from
two childhood-onset type 1 diabetes registries. Diabet Med
2011;28:293–300.
5. Beregszaszi M, Tubiana-Rufi N, Benali K, et al. Nocturnal
hypoglycaemia in children and adolescents with insulin-dependent
diabetes mellitus: prevalence and risk factors. J Pediatr
1997;131:27–33.
6. Williams RM, Dunger DB. Insulin treatment in children and
adolescents. Acta Paediatr 2004;93:440–6.
7. Davis EA, Keating B, Byrne GC, et al. The impact of improved
glycaemic control on rates of hypoglycaemia in insulin dependent
diabetes mellitus. Arch Dis Child 1998;78:111–15.
8. Bulsara MK, Davis EA, Holman CD, et al. The impact of a decade of
changing of severe hypoglycaemia in a population-based cohort of
children with type 1 diabetes. Diabetes Care 2004;27:2293–8.
9. Cryer PE. The barrier of hypoglycaemia in diabetes. Diabetes
2008;57:3169–76.
10. Hovorka R. Continuous glucose monitoring and closed-loop
systems. Diabet Med 2006;23:1–12.
11. Hovorka R, Elleri D, Hood T, et al. Overnight closed loop insulin
delivery in young people with type 1 diabetes: a free-living
randomised clinical trial. Diabetes Care. In press. doi:10.2337/
DC13-2644
12. Strauss A, Corbin J. Basics of qualitative research: grounded theory
procedures and techniques. London: Sage, 1990.
13. JDRF Continuous Glucose Monitoring Study Group. Validation of
measures of satisfaction with and impact of continuous and conventional
glucose monitoring. Diabetes Technol Ther 2010;12:679–84.
14. Cox DJ, Irvine A, Gonder-Frederick L, et al. Fear of hypoglycemia:
quantification, validation, and utilization. Diabetes Care 1987;10:617–21.
15. Gonder-Frederick L, Schmidt KM, Vajda KA, et al. Psychometric
properties for Hypoglycaemia Fear Survey II for adults with type 1
diabetes. Diabetes Care 2011;34:801–6.
16. Clarke WL, Gonder-Frederick A, Snyder AL, et al. Maternal fear of
hypoglycemia in their children with insulin dependent diabetes
mellitus. J Pediatr Endocrinol Metab 1998;11(Suppl 1):189–94.
BMJ Open Diabetes Research and Care 2014;2:000025. doi:10.1136/bmjdrc-2014-000025 7
Clinical care/education/nutrition/psychosocial research
